Triple-drug Chemo with Topotecan Helps Preserve Vision in Patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Revamping front-line multi-drug chemotherapy for retinoblastoma to include topotecan helped to maintain high cure rates for the eye cancer while preserving patients’ vision and reducing their risk of treatment-related leukemia. Results of the St. Jude Children’s Research Hospital study appear online today in the Journal of Clinical Oncology.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Vinay Prasad, a MAHA-aligned hematologist-oncologist with an avid cyber following, was named director of the FDA Center for Biologics Evaluation and Research, where he will be responsible for the agency’s regulation of vaccines and biologics, including cell and gene therapies.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login